Skip to content

Early Stage or No Cancer Detected (Stage I) 

TNM Values:

cT1
N0, M0
PSA < 10
Grade Group 1

Based on your responses, the cancer appears to be in an early stage (Stage I) or not detected. Typically, Stage I prostate cancer corresponds to TNM values of T1 or T2a, N0, M0, indicating a tumor that is confined within the prostate and not spread to lymph nodes or distant sites. Regular monitoring and consultation with a healthcare professional are essential for managing this stage of prostate cancer.

Localized Prostate Cancer

The NCCN Guidelines provide comprehensive recommendations for the treatment of localized prostate cancer. These include initial risk stratification and staging workup, which involves assessing clinical/pathological features and additional evaluations. The guidelines recommend various treatment options based on risk groups.

Risk LevelRecommended Treatment
Very-Low-Risk and Low-RiskActive surveillance (AS) is recommended.
Favorable Intermediate-RiskTreatment options include AS, external beam radiation therapy (EBRT)/brachytherapy, radical prostatectomy, and observation, depending on life expectancy.
Unfavorable Intermediate-RiskRecommended treatments are EBRT with androgen deprivation therapy (ADT) for 4-6 months, radical prostatectomy with pelvic lymph node dissection (PLND) if the risk of lymph node metastasis is ≥two percent, or observation for men with low survival expectancy.
High- and Very-High-RiskMultimodal therapy (such as EBRT + 1.5-3 year ADT + docetaxel for very high-risk disease), radical prostatectomy with PLND, or observation for asymptomatic patients with low survival expectancy are recommended.

Updates in 2022: The guidelines have included the use of Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET/CT or PET/MRI for bone and soft tissue imaging. Also, EBRT+ADT+abiraterone acetate is added for high- or very-high-risk groups. The panel emphasizes the use of nomograms and consideration of various demographic and clinical factors for individualized treatment discussions​​.

It’s important to note that while this information provides an overview of the NCCN Guidelines for localized prostate cancer, accessing the full guidelines would give a more detailed and comprehensive understanding of the treatment options and recommendations.